Darracq MA, Comment. Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. Ann Pharmacother. 2012;46(4):611–2. https://doi.org/10.1345/aph.1P787a. author reply 3.

Article  PubMed  Google Scholar 

Sokoro AA, Zivot J, Ariano RE. Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. Ann Pharmacother. 2011;45(9):e50. https://doi.org/10.1345/aph.1P787.

Article  PubMed  Google Scholar 

Fernández M, Lago L, Alonso MG, Guede A, Benavente JL, Olivares JM. Serotonin syndrome versus neuroleptic malignant syndrome: a case report. Actas Esp Psiquiatr. 2018;46(2):68–74.

PubMed  Google Scholar 

Dosi R, Ambaliya A, Joshi H, Patell R. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep. 2014. https://doi.org/10.1136/bcr-2014-204154. 2014.

Article  PubMed  PubMed Central  Google Scholar 

Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. Handb Clin Neurol. 2018;157:663–75. https://doi.org/10.1016/b978-0-444-64074-1.00039-2.

Article  PubMed  Google Scholar 

Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;20(1). https://doi.org/10.4088/PCC.17r02185.

Maitland S, Baker M. Serotonin syndrome. Drug Ther Bull. 2022;60(6):88–91. https://doi.org/10.1136/dtb.2021.000032.

Article  PubMed  Google Scholar 

Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome-A focused review. Basic Clin Pharmacol Toxicol. 2023;133(2):124–9. https://doi.org/10.1111/bcpt.13912.

Article  CAS  PubMed  Google Scholar 

Prakash S, Lodha D, Rawat KS. Coexistence of serotonin syndrome and neuroleptic malignant syndrome: does it exist? BMJ Case Rep. 2021;14(8). https://doi.org/10.1136/bcr-2021-241578.

Katus LE, Frucht SJ. Management of Serotonin Syndrome and neuroleptic malignant syndrome. Curr Treat Options Neurol. 2016;18(9):39. https://doi.org/10.1007/s11940-016-0423-4.

Article  PubMed  Google Scholar 

Hadad E, Weinbroum AA, Ben-Abraham R. Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med. 2003;10(2):149–54. https://doi.org/10.1097/00063110-200306000-00018.

Article  PubMed  Google Scholar 

Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23(Suppl 1):15–26. https://doi.org/10.1002/hup.918.

Article  PubMed  Google Scholar 

Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24(2):155–62.

PubMed  Google Scholar 

Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother. 2016;50(11):973–81. https://doi.org/10.1177/1060028016657553.

Article  CAS  PubMed  Google Scholar 

Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998;155(8):1113–6. https://doi.org/10.1176/ajp.155.8.1113.

Article  CAS  PubMed  Google Scholar 

Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015;15(1):45–62. https://doi.org/10.1007/s40268-014-0078-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinsonism Relat Disord. 2003;9(Suppl 1). https://doi.org/10.1016/s1353-8020(02)00125-6. :S3-9.

Rainer C, Scheinost NA, Lefeber EJ. Neuroleptic malignant syndrome. When levodopa withdrawal is the cause. Postgrad Med. 1991;89(5):175–8. https://doi.org/10.1080/00325481.1991.11700900.

Article  CAS  PubMed  Google Scholar 

Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth. 2020;124(1):44–62. https://doi.org/10.1016/j.bja.2019.08.010.

Article  CAS  PubMed  Google Scholar 

Bartlett D. Drug-Induced Serotonin Syndrome. Crit Care Nurse. 2017;37(1):49–54. https://doi.org/10.4037/ccn2017169.

Article  PubMed  Google Scholar 

Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb-drug interactions: a literature review. Drugs. 2005;65(9):1239–82. https://doi.org/10.2165/00003495-200565090-00005.

Article  CAS  PubMed  Google Scholar 

Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 2018;92(8):2457–73. https://doi.org/10.1007/s00204-018-2244-6.

Article  CAS  PubMed  Google Scholar 

Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019;12:1178646919873925. https://doi.org/10.1177/1178646919873925.

Article  PubMed  PubMed Central  Google Scholar 

Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf. 1998;19(1):73–82. https://doi.org/10.2165/00002018-199819010-00006.

Article  CAS  PubMed  Google Scholar 

Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41–7. https://doi.org/10.1177/1941875210386491.

Article  PubMed  PubMed Central  Google Scholar 

Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49(448):871–4.

CAS  PubMed  PubMed Central  Google Scholar 

Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277–85. https://doi.org/10.1081/clt-120037428.

Article  CAS  PubMed  Google Scholar 

Adell A. Brain NMDA receptors in Schizophrenia and Depression. Biomolecules. 2020;10(6). https://doi.org/10.3390/biom10060947.

Laszlovszky I, Barabássy Á, Németh G, Cariprazine. A broad-spectrum antipsychotic for the treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021;38(7):3652–73. https://doi.org/10.1007/s12325-021-01797-5.

Article  PubMed  PubMed Central  Google Scholar 

Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. New atypical antipsychotics in the treatment of Schizophrenia and Depression. Int J Mol Sci. 2022;23(18). https://doi.org/10.3390/ijms231810624.

Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet. 2023;401(10371):141–53. https://doi.org/10.1016/s0140-6736(22)02080-3.

Article  CAS  PubMed  Google Scholar 

Preda A, Shapiro BB. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020;19(12):1529–38. https://doi.org/10.1080/14740338.2020.1832990.

Article  CAS  PubMed  Google Scholar 

Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77. https://doi.org/10.2147/tcrm.S117321.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheniaux E, Nardi AE. Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf. 2019;18(10):893–913. https://doi.org/10.1080/14740338.2019.1651291.

Article  CAS  PubMed  Google Scholar 

Sommer BR, Fenn H, Pompei P, DeBattista C, Lembke A, Wang P, et al. Safety of antidepressants in the elderly. Expert Opin Drug Saf. 2003;2(4):367–83. https://doi.org/10.1517/14740338.2.4.367.

Article  CAS  PubMed  Google Scholar 

Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270–88. https://doi.org/10.1159/000447034.

Article  PubMed  Google Scholar 

Yunusa I, Rashid N, Demos GN, Mahadik BS, Abler VC, Rajagopalan K. Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment of dementia-related psychosis: a Network Meta-analysis. Adv Ther. 2022;39(5):1993–2008. https://doi.org/10.1007/s12325-022-02075-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheltema Beduin A, de Haan L. Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull. 2010;43(3):45–81.

PubMed  Google Scholar 

Hefner G, Wolff J, Toto S, Reißner P, Klimke A. Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. J Neural Transm (Vienna). 2022;129(11):1353–65. https://doi.org/10.1007/s00702-022-02542-0.

Article  CAS  PubMed  Google Scholar